ArticleInternational journal of laboratory hematology2021
Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure.
Open access · greenAbstract readLetter
In one paragraph
Article in International journal of laboratory hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Clinical profiling of AML1::ETO and KIT exon 17 mutation in pediatric AML by high-throughput drug sensitivity.BMC cancer · 2026Article
- Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics.Therapeutic advances in hematology · 2025Review
- Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16).BMC cancer · 2023Article
- Comprehensive analysis for cellular senescence-related immunogenic characteristics and immunotherapy prediction of acute myeloid leukemia.Frontiers in pharmacology · 2022Article
- Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance.Nature communications · 2021Article
- How to Improve Prognostication in Acute Myeloid Leukemia withBiomedicines · 2021Review
- Emerging therapies for inv(16) AML.Blood · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 19 institutions in 5 countries.
Celalettin UstunDivision of Hematology, Oncology and Cellular Therapy, Rush University, Chicago, IL, USA.ORCID 0000-0001-6896-6213
Elizabeth A MorganDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5880-9337
Ethan M RitzRush Bioinformatics and Biostatistics Core, Rush University, Chicago, IL, USA.
Hanne VestergaardDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Sheeja PullarkatDepartment of Pathology, University of California, Los Angeles, CA, USA.
Philip M KluinDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Robert OhgamiDepartment of Pathology, Stanford University, Stanford, CA, USA.
Linda B BaughnDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Young KimDepartment of Pathology, City of Hope National Medical Center, Duarte, CA, USA.
Nam K KuDepartment of Pathology, University of California, Los Angeles, CA, USA.
David CzuchlewskiDepartment of Pathology, University of New Mexico, Albuquerque, NM, USA.
Michael Boe MøllerDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Ana-Iris SchieferDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Krzysztof MrózekThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Hans-Peter HornyInstitute of Pathology, Ludwig-Maximilians-University, Munich, Germany.
Tracy I GeorgeDepartment of Pathology, University of New Mexico, Albuquerque, NM, USA.ORCID 0000-0001-5478-7847
Thomas Kielsgaard KristensenDepartment of Pathology, Odense University Hospital, Odense, Denmark.
Todd BeckRush Bioinformatics and Biostatistics Core, Rush University, Chicago, IL, USA.
Sunita NathanDivision of Hematology, Oncology and Cellular Therapy, Rush University, Chicago, IL, USA.
Cecilia Arana YiDepartment of Pathology, University of New Mexico, Albuquerque, NM, USA.
Cecilia YeungFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Vinod PullarkatDivision of Hematology and HCT, City of Hope, Duarte, CA, USA.ORCID 0000-0001-9129-3424
Jason GotlibStanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, USA.
Cem AkinDivision of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, MI, USA.
Jessica KohlschmidtThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Amandeep SalhotraDepartment of Pathology, City of Hope National Medical Center, Duarte, CA, USA.
Lori SomaUniversity of Washington School of Medicine, Seattle, WA, USA.ORCID 0000-0003-0606-899X
Dong ChenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Se Y HanDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Christina ChoDepartment of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wolfgang SperrDepartment of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-3288-8027
Sigurd Broesby-OlsenMastocytosis Center Odense University Hospital, Odense, Denmark.
Michael A LindenDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Michelle DolanDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Gregor HoermannDivision of Medical and Chemical Laboratory Diagnostics - Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Jason L HornickDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6475-8345
Clara BloomfieldThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Ryo NakamuraDivision of Hematology and HCT, City of Hope, Duarte, CA, USA.
H Joachim DeegFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Mark R LitzowDepartment of Internal Medicine and Division of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-9816-6302
Gautam BorthakurDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7679-6453
Daniel WeisdorfDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Gerwin HulsDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Miguel-Angel PeralesDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Peter ValentDepartment of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Guido MarcucciDivision of Hematology and HCT, City of Hope, Duarte, CA, USA.
University of Minnesota · USMedical University of Vienna · ATOdense University Hospital · DKCity of Hope · USMayo Clinic in Arizona · USRush University · USThe Ohio State University · USUniversity of New Mexico · USUniversity of Washington · USBrigham and Women's Hospital · USCity Of Hope National Medical Center · USStanford University · USUniversity Medical Center Groningen · NLUniversity of California, Los Angeles · USCornell University · USLudwig-Maximilians-Universität München · DEMemorial Sloan Kettering Cancer Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Michigan · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdolescentAdultAgedAge FactorsChildChild, PreschoolCore Binding Factor beta SubunitFemaleHumansLeukemia, Myeloid, AcuteLeukocyte CountMaleMiddle AgedOncogene Proteins, FusionPrognosisRetrospective StudiesCBFB protein, humanCore Binding Factor beta Subunitinv(16) fusion protein, humanOncogene Proteins, Fusion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.